JPRN-C000000232
Completed
未知
A randomized, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day) - Preventive effect on acute exacerbation of chronic obstructive pulmonary disease with Carbocisteine (PEACE Study)
Department of Respiratory Medicine Juntendo University, School of Medicine0 sites150 target enrollmentDecember 1, 2006
ConditionsCOPD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- Department of Respiratory Medicine Juntendo University, School of Medicine
- Enrollment
- 150
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Intolerance for Carbocisteine 2\. Use of mucolytic agents within one month prior to beginning of the study 3\. Use of antibiotics at the beginning of the study 4\. Bronchiectasis, pneumonia, interstitial lung disease, tuberculosis 5\. Carcinoma 6\. Previous lung transplant or lung volume reduction surgery 7\. Pregnant or breastfeeding 8\. Attendance in the other study within 3 months prior to the beginning of the study 9\. Underlying severe disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyEUCTR2007-003723-21-DEovartis Pharma Services AG525
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiency - NDEUCTR2007-003723-21-ITOVARTIS FARMA300
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyDiabetes Type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-003723-21-FIovartis Pharma Services AG300
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiencyDiabetes Type 2EUCTR2007-003723-21-SEovartis Pharma Services AG525
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 diabetes and moderate renal insufficiencyEUCTR2007-003723-21-FRovartis Pharma Services AG300